Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era by Haugeberg, Glenn et al.
Haugeberg et al. BMC Musculoskeletal Disorders 2014, 15:289
http://www.biomedcentral.com/1471-2474/15/289RESEARCH ARTICLE Open AccessGeneralized bone loss in early rheumatoid
arthritis patients followed for ten years in the
biologic treatment era
Glenn Haugeberg1,2*, Knut Bjørn Helgetveit3, Øystein Førre4, Torhild Garen4, Hege Sommerseth3 and Anne Prøven3Abstract
Background: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). Biologic disease
modifying anti rheumatic drugs (DMARDs) has been shown to be superior to synthetic DMARDs to reduce bone
destruction including generalized bone loss in RA. Our aim was to study short- and long term changes in hip and spine
bone mineral density (BMD) in early RA patients treated during the first decade with available biologic DMARDs.
Methods: RA patients diagnosed at an out-patient clinic between 1999 and 2001 were consecutively enrolled.
Demographic, disease and treatment data were collected and BMD was assessed by dual energy X-ray
absorptiometry at baseline and after 2, 5 and 10 years.
Results: The 92 included RA patients had a baseline mean age (SD) of 50.9 (13.3) years and symptom duration of
12.4 (6.7) months, 62.0% were women and 66.3% were RF positive. In the first 2 years ever use of biologic DMARDs
was 18.5%, synthetic DMARDs 91.3% and prednisolone 62.0% whereas the figures for the subsequent 8 years were
62.6%, 89.2% and 51.4%, respectively. The annual rate of BMD loss in the first 2 years and the subsequent 8 years
was at femoral neck −1.00% vs. −0.56%, at total hip −0.96% vs. −0.41% and at spine L1−4 -0.42% vs. 0.00%.
Conclusions: Our study adds evidence that aggressive anti-inflammatory treatment including biologic DMARDs
reduces the rate of bone loss in RA. Indicating that the burden of osteoporosis is reduced in RA patients treated in
clinical practice in the new millennium.Background
Osteoporosis and its clinical consequence fracture is a
well-known extra articular manifestation in rheumatoid
arthritis (RA). In both male and female RA populations
the prevalence of reduced bone density has been reported
to be doubled compared to the background population
[1,2]. Patients with RA are at increased risk for both verte-
bral [3] and non-vertebral fractures [4]. Generalized bone
loss assessed at hip or spine occurs early in the disease [5]
and is related to inflammatory activity [6].
During the last 10–15 years the importance of treating
RA patients towards remission or low disease activity
using outcome measures has been well documented and* Correspondence: glenn.haugeberg@sshf.no
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article, unless otherwise stated.become the recommended treatment strategy [7]. In the
same time period new potent anti-inflammatory drugs
the biologic disease modifying anti-rheumatic drugs
(DMARDs) has become available for clinical use [8].
Treatment with biologic DMARDs, e.g. tumor necrosis
factor alpha (TNF) inhibitors has been shown not only to
reduce the development of erosion but also to reduce the
rate of generalized bone loss in RA [9-11]. Studies have
been performed to examine bone loss in RA [5,6,9-14].
These studies however are limited by their rather short
observational period. Furthermore there is a lack of long
term follow up studies following patients from the early
phase of the disease.
Thus the primary aim of the present study was to exam-
ine short term and long term changes in bone density at
hip and lumbar spine in patients with early RA treated
during the last decade. Second to search for predictors
and associates with change in bone density.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patients, disease measures and treatment
In an out-patient rheumatology clinic between 1999 and
2001 patients diagnosed with RA were consecutively
included in a prospective observational follow up study.
The patients had to fulfil the American College of
Rheumatology 1987 revised classification criteria for RA
[15]. According to protocol collection of demographic,
clinical and treatment data was done at inclusion and
after 6 months, 2, 5 and 10 years follow up. At all visits,
data for demographic variables, disease characteristics,
disease activity and health status were collected either
by interview, clinical assessment, questionnaires or by
reviewing the medical records. Disease activity was
assessed by c-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR) and the composite disease activ-
ity score (DAS) calculated from 28 swollen and 28
tender joint count and ESR (DAS28ESR3). We used
DAS28ESR3 because data on patient’s global assess-
ment used for DAS calculation was not collected. We
also registered data for rheumatoid factor (RF) at base-
line and anti-cyclic citrullinated peptide (anti-CCP)
during follow up. Modified Health Assessment Ques-
tionnaire (MHAQ) was used for assessment of physical
function [16].
At all visits the use of prednisolone and synthetic and
biologic DMARDs were registered. Furthermore treat-
ment information in-between the visits were collected
based on information in the medical records which also
included the use of intra-muscular and intra-articular
glucocorticosteroids (GC) and osteoporosis treatment.
Cumulative doses of GC were calculated and transformed
into prednisolone equivalent doses.
At 10 years visit serum 25-hydroxyvitamin D (s-25(OH)
D) was measured. Severe vitamin D deficiency was defined
as s-25(OH) D levels lower than 12.5 nmol/l and moderate
deficiency as 12.5-25 nmol/l [17].Bone density
Bone mineral density (BMD) was assessed at baseline,
2, 5 and 10 years follow up using the same dual energy
X-ray absorptiometry (DXA) equipment (Lunar Prod-
ogy). Trained osteoporosis nurses performed all stan-
dardized BMD measurements at hip (femoral neck and
total hip) and lumbar spine L1-4. Left hip was mea-
sured. If left hip could not be measured the right hip
was measured. The DXA machine was stable for the
whole period. Long term spine phantom precision
expressed as coefficient of variation (CV) was 0.68%.
In vivo-short term precision based on duplicate meas-
urement of 30 individuals was for femoral neck left
side 1.93% and right side 1.80%, for total hip left side
0.79% and right side 0.75% and for spine L1-4 0.88%.Analysis and statistical tests
Due to a delay in installing the DXA machine at the hos-
pital prior to study start, BMD in the first 42 included
RA patients could not be measured at baseline. Missing
baseline BMD values was calculated from the patient’s
2 years BMD value and adjusted for the mean percent-
age change calculated from all patients with available
baseline and 2 years BMD data. In patients with missing
DXA data between two measurement time points miss-
ing BMD was calculated using the annual percentage
change adjusted for the time period. The BMD data
were analyzed with the available data and with imput-
ation of missing data separately.
For descriptive statistics continuous variables with nor-
mal distribution was presented as mean with standard devi-
ation (SD) or with 95% confidence interval (CI) whereas
variables with non-normal distribution also were presented
with median and interquartile range [IQR]. Categorical
variables were presented as numbers and percentage.
Percentage BMD change between DXA measurement
periods was calculated.
For group comparison, we used t-test for continuous
variables if normal distributed and Mann–Whitney U
test if not normal distributed and chi-square test for
categorical variables.
To explore for predictors and associates with change in
BMD for the period 0–2 years and 2–10 years, we used
unadjusted and adjusted linear regression analysis. For the
multivariate linear regression models we used forward
procedure. Included were variables with a p value ≤0.1
tested in univariate linear regression.
Statistical tests were performed using PASW Statistics
18 (IBM SPSS statistics). Significance level was p < 0.05.
Ethics and legal aspects
The study was approved by the regional committee for
ethics and medical research, health region II in Norway
(REK-S-98093). All patients gave written informed consent
before inclusion.
Results
Patients, disease measures and treatment
A total of 94 RA patients were included. Two patients had
only baseline DXA values and were excluded from the
analysis. Among the 92 patients (35 men and 57 women)
91 were Caucasian and 1 was Asian. Baseline patient char-
acteristics for demographic, disease measures, disease ac-
tivity and health status are shown in Table 1. For variables
listed in Table 1 a statistical significant difference between
men and women was only shown for age (mean 55.5 vs.
48.0 years, p = 0.008), weight (mean 84.3 vs. 68.5 kg, p <
0.001), height (mean 1.78 vs. 1.63 m, p < 0.001) and CRP
(mean 40.1 vs. 21.9 mg/dl, p = 0.014, median 27.5 vs. 13.0,
p = 0.025).
Table 1 Baseline characteristics in 92 early rheumatoid
arthritis patients
Patient data
Age (years) 50.9 (13.3)
Women 57 (62.0)
Females in menopause (n = 51)* 36 (70.6)
Weight (kg) 74.5 (16.9)
Height (m) 1.69 (0.10)
BMI (kg/m2) 25.8 (4.4)
Current smoking 35 (38.0)
Disease data
Symptom/disease duration (months) 12.4 (6.7)
Anti-CCP positive, (n = 82)** † 54 (65.9)
High titer CCP positive >3X‡ (n = 82)** 52 (63.4)
RF positive, (n = 86)* 57 (66.3)
High titer RF positive >3X‡ (n = 86)** 46 (53.5)
ESR (mm/hr)
29.6 (21.2)
24.5 [21.0]
CRP (mg/dl) (n = 90)**
28.8 (34.4)
17.5 [27.3]
DAS28ESR3 5.2 (1.1)
MHAQ (0–3) (n = 91)**
0.68 (0.51)
0.63 [0.75]
Continuous variables with normal distribution are presented as mean with
standard deviation (SD) whereas variables with non-normal distribution are
also presented as median with interquartile range [IQR]. Categorical variables
are presented as numbers and percentage (%).
*Varies from 57 due to missing values.
**Varies from 92 due to missing values.
†Anti-CCP data are the first available values in medical records.
‡Values three times higher than upper limit of normal values for the test.
BMI: Body mass index; Anti-CCP: Anti cyclic citrullinated peptide; RF:
Rheumatoid factor; ESR: Erythrocyte sedimentation rate; CRP: C-reactive
protein; DAS28ESR3: Disease activity score based on 28 joint count (swollen
and tender joints) and ESR; MHAQ: Modified health assessment questionnaire.
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DAS28ESR3 and MHAQ and the use of biologic and
synthetic DMARDs and GC for the 0–2 years and 2–10
years period.
The ever use of biologic DMARDs increased from 18.5%
in the period 0–2 years to 62.6% in the period 2–10 years.
All patients treated with biologic DMARDs had been using
TNF inhibitors. The median dose among users of prednis-
olone was 5.0 mg at all follow up visits with a range of
2.5 mg to 15.0 mg. No statistically significant differences
were seen between men, pre- and post-menopausal women
on the use of synthetic DMARDs, biologic DMARDs, pred-
nisolone, any GC use or cumulative GC dose for the two
first years and the subsequent eight years of follow up.
During follow up minor differences between men and
women and between pre- and post-menopausal women
was found for disease measures and treatment listed
in Table 2.During follow up 16.3% (5 men and 10 women) were
using anti-resportive osteoporosis treatment (ART), 4
oestrogen and 11 bisphosphonates and 70.7% (23 men
and 42 women) were using calcium and/or vitamin D.
At 10 years visit 93.2% (69 out of 74 patients) had vita-
min D measured. Mean (SD) value for s-25(OH) D was
72.9 (26.1) nmol/l. None had severe vitamin D deficiency
(<12.5 nmol/l) and only two patients had moderate vita-
min D deficiency (12.5-25.0 nmol/l).
Bone density
Among the 92 included patients 74 (80.4%) patients had
their last DXA performed at 10 years, 14 (15.2%) pa-
tients at 5 years and 4 (4.3%) patients at 2 years follow
up. Apart from missing values at baseline (42 patients)
as described in material and method section 3 patients
did not have DXA measurement performed at 2 years
follow up and 6 patients at 5 years follow up. In 7 pa-
tients right hip instead of left hip was measured.
As shown in Figure 1 a significant bone loss (p <
0.001) was found between baseline and 2, 5 and 10 years
follow up at femoral neck and total hip but not at
lumbar spine.
The annual rate of bone loss for the period’s baseline
to 2 year, 2 to 5 years, 5 to 10 years and 2 to 10 years
follow up was at femoral neck −1.00%, −0.68%, −0.54%
and −0.56% and at total hip −0.96%, −0.39%, −0.46%
and −0.41%, and at spine L1-4 −0.42%, +0.04%, −0.09%
and 0.0%, respectively. The annual rate of bone loss in
the first 2 years was significantly higher in patients
treated with biologic DMARDs compared with non bio-
logic DMARDs treated patients at femoral neck (−2.07%
vs −0.74%, p = 0.019) and total hip (−1.92 vs. −0.76%,
p = 0.034) but not at lumbar spine L1-4 (−1.27% vs. −0.21%,
p = 0.10). No significant differences in bone loss was
found between the biologic and non biologic DMARD
treated patients neither for the 2–5 years period (fem-
oral neck −0.87% vs. −0.52%, total hip −0.57% vs. -0.28%,
spine L1-4 −0.39% vs. 0.50%), the 5–10 years period (fem-
oral neck −0.46% vs. −0.64%, total hip −0.41% vs. -0.23%,
spine L1-4 −0.02% vs. −0.17%) or for the whole 2–10 years
period (femoral neck −0.56% vs. −0.56%, total hip −0.32%
vs. −0.49%, spine L1-4 −0.13% vs. 0.19%). When the data
were analyzed comparing patients who were treated with
biologic DMARDs and/or prednisolone with patients who
were not treated with these drugs the same overall pattern
was seen (data not shown).
As shown in Figure 2 a statistical significant difference
in annual percentage bone loss between men and
women was seen for the 2–10 years but not for the 0–2
years period.
In 8 patients (7 men and 1 woman) in the period 2–10
years annual gain in spine L1-4 BMD exceeded one per-
cent (range 1.03% − 4.89%). Mean age in these eight
Table 2 Disease measures and treatment in 92 early rheumatoid arthritis patients followed for 10 years
Period 0–2 years (n = 92) Period 2–10 years (n = 74) P value
Mean ESR (mm/hr) 21.2 (12.0)† 13.2 (6.8)‡ <0.001
Mean CRP (mg/dl) 18.8 (14.9)† 8.1 (7.0)‡ <0.001
14.7 [18.0] 5.5 [8.6]
Mean DAS28ESR3 4.17 (0.88)† 2.92 (0.82)‡ <0.001
Mean MHAQ (0–3) 0.42 (0.30)† 0.27 (0.27)‡ <0.001
0.33 [0.45] 0.18 [0.42]
Ever users synthetic DMARDs 84 (91.3) 66 (89.2) <0.001
Ever users methotrexate 71 (77.2) 61 (82.4) <0.001
Ever users biologic DMARDs 17 (18.5)* 46 (62.6)** <0.001
Ever users prednisolone 57 (62.0) 38 (51.4) <0.001
Ever users any GC*** 76 (82.6) 59 (79.7) 0.400
Mean prednisolone equivalent dose (gram)**** 4.56 (4.71) 7.29 (10.53) 0.012
2.77 [7.50] 2.09 [11.53]
Continuous variables with normal distribution are presented as mean with standard deviation (SD) whereas variables with non-normal distribution also are
presented as median with interquartile range [IQR]. Categorical variables are presented as numbers and percentage (%).
†Calculated from baseline, 6 months and 2 years data.
‡Calculated from 2 years 5 years and 10 years data.
*All treated with tumor necrosis factor inhibitors.
**All treated with tumor necrosis factor inhibitors, 6 patients also had been treated with other biologic DMARDs (rituximab and/or tocilizumab).
***Includes prednisolone, intraarticular and intramuscular GC injections.
****The cumulative doses of any GC given were calculated and transformed into prednisolone equivalent doses.
ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28ESR3: Disease activity score based on 28 joint count (swollen and tender joints) and ESR MHAQ:
Modified health assessment questionnaire; DMARDs: Disease modifying anti-rheumatic drugs; GC: Glucocorticosteroids.
Figure 1 Percentage change (mean with 95% confidence interval) in bone mineral density (BMD) at femoral neck, total hip and spine
L1-4 after 2, 5 and 10 years follow up in early rheumatoid arthritis patients. Numbers below the graph shows the mean percentage BMD
change with standard error of mean (SEM) for the period and baseline BMD values (g/cm2) with standard deviation (SD) for patients with follow up data.
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Figure 2 Annual change (mean percentage with 95% confidence intervals of mean) in bone mineral density (BMD) at femoral neck
(fem.neck), total hip and spine L1-4 for the first 2 years period and for the subsequent 8 years period in men and women with early
rheumatoid arthritis followed for up to 10 years.
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these patients areas with increase of more dense bone and
signs of new bone formation present as osteophytes were
visible explaining the increase in bone density.
As shown in Figure 3 a difference in annual rate of
bone loss between pre- and post-menopausal women
was seen for the period 2–10 years but not for the
period 0–2 years.
No statistically significant differences in BMD change
were seen between men and pre-menopausal women for
the 0–2 years and the 2–10 years period apart from an-
nual change in bone density at spine L1-4 for the 2–10
years period. Between men and post-menopausal women
a statistically significant difference in change in bone
density was seen at hip and spine for the 2–10 years
period but not for the 0–2 year period.
No statistically significant difference in bone change
during follow up was seen either between never and ever
users of ART.
Validity of BMD results using imputation of missing data
Between patients with and without DXA baseline values
no significant difference was seen for BMD at femoral
neck, total hip and spine L1-4 at 2, 5 and 10 years follow
up, or for changes in bone density between 2 and 5, 2
and 10 and 5 and 10 years follow up. Further no statisti-
cally significant difference was seen between the twogroups for variables listed in Tables 1 and 2, this both at
baseline, at 2 years follow up and in-between.
When only patients with available data at all visits
were analyzed the same magnitude and pattern of bone
loss was seen compared to when data were handled
with imputation of missing data as shown in Figure 1.
The mean BMD change for baseline-2 years, baseline-
5 years and baseline-10 years follow up was at femoral
neck (n = 36) −1.75%, −4.61%, −6.83% at total hip
(n = 36) −1.07%, −3.20%, −4.81% and at spine L1-4
(n = 28) −0.54%, −1.33% and −1.55%, respectively.
Fractures
One patient had an ankle and a femur fracture and two
patients had clinical costa fracture during follow up.
Associates with change in bone density during follow up
The baseline variables listed in Table 1 and mean values of
disease measures (ESR, CRP, DAS28ESR3 and MHAQ,)
and treatment (ART, DMARDs, biologic DMARDs and
GC) during follow up listed in Table 2 was one by one
tested for their association with bone loss for the first 0–2
year period and for the 2–10 year period.
For the baseline disease measures ESR, CRP, DAS28ESR3
and MHAQ a statistically significant or a border significant
association with bone loss was only found for the 0–2 year
period for MHAQ (B-0.015 P = 0.047) and DAS28ESR3 (B-
Figure 3 Annual change (mean percentage with 95% confidence intervals of mean) in bone mineral density (BMD) at femoral neck
(fem.neck), total hip and spine L1-4 for the first 2 years period and for the subsequent 8 years period in women with pre- and
post-menopausal status with early rheumatoid arthritis followed for 10 years.
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P = 0.050), DAS28ESR3 (B −0.018 P < 0.001) and
MHAQ (B-0.030 P = 0.004) at spine L1-4.
In Table 3 variables with an association with BMD
change (p value ≤ 0.1) for the 0–2 year period and/or the
2–10 years period at femoral neck and/or total hip and/
or spine are shown.
In the multivariable models with forward procedure
variable independently associated with loss in BMD for
the 0–2 years period was for femoral neck ever use of
biologic DMARDs (B −0.023, p = 0.024), for total hip cu-
mulative dose of GC (B −0.003, p = 0.003) and for spine
L1-4 DAS28ESR3 (B −0.013, p = 0.037). Variables inde-
pendently associated with change in bone density for the
2–10 years follow up period was for femoral neck meno-
pause (B −0.042, p = 0.001) and smoking (B −0.034,
p = 0.008), for total hip menopause (B −0.059, p < 0.001) and
smoking (B −0.033, p = 0.011) and for spine L1-4 female
gender (B −0.105, p < 0.001) and RF (B −0.056, p = 0.015).
Discussion
In our prospective observational study of early RA pa-
tients the annual rate of bone loss was higher in the 0–2
year period compared with the 2–10 year period. This
was however only seen in men and in premenopausal
women and not in post-menopausal women. In the 0–2
year period disease and treatment variables were morefrequently found to be associated with bone loss than
well known risk factors for osteoporosis e.g. smoking
and post-menopausal status, whereas the opposite was
seen for the 2–10 years period.
A high rate of generalized bone loss in early RA pa-
tients has been reported from the pre-biologic era [5,6].
In one study the annual rate of bone loss was reported to
be −3.6% at femoral neck and −2.1% at lumbar spine [6]
and in another study −1.7% at femoral neck and −2.7% at
lumbar spine [5]. These figures are significantly higher
than found in our study. This is most likely explained by
the high proportion of patients treated with biologic
DMARDs in our study. In the 0–2 year period 18.5% and
in the 2–10 year period 62.6% were ever users of biologic
DMARDs.
In the literature there is convincing evidence that
treatment with TNF inhibitors reduces generalized bone
loss in RA patients [9-11]. The bone protective effect of
TNF inhibitors in RA patients may not only be ex-
plained by the strong anti-inflammatory properties of
TNF inhibitors. Anti-TNF therapy has been shown to re-
duce radiographic joint damage and peri-articular bone
loss in RA independent of clinical response [18,19].
GCs are known as potent anti-inflammatory drugs and
are frequently used in RA, however, they also cause
osteoporosis [20,21]. In RA this negative effect of GC on
bone has been questioned. Studies have even reported
Table 3 Associates with bone loss in 92 rheumatoid arthritis patients followed for 10 years
Change in bone mineral density
Femoral neck Total hip Spine L1-4
0-2 yrs 2-10 yrs 0-2 yrs 2-10 yrs 0-2 yrs 2-10 yrs
Beta Beta Beta Beta Beta Beta
p value p value p value p value p value p value
Age (yrs) - - - - - B 0.244 P = 0.048
Women (N/Y) - B-0.029 P = 0.027 - B-0.039 P = 0.004 - B-0.104 P = 0.000
Menopause (N/Y) - B-0.033 P = 0.049 B 0.016 P = 0.076 B-0.053 P = 0.003 - B-0.051 P = 0.063
Smoking (N/Y) - B-0.028 p = 0.036 - B-0.024 P = 0.080 - -
RF (N/Y) - B-0.030 P = 0.030 - B-0.029 P = 0.047 - B-0.053 P = 0.044
MHAQ (0–3) B −0.027 p = 0.034 - - - - -
ESR (mm/hr) - - - - B-0.189 P = 0.092
DAS28ESR3 B −0.010 P = 0.030 B-0.015 P = 0.057 - B-0.016 P = 0.055 B-0.013 P = 0.037 -
Ever use of biologic
DMARDs (N/Y)
B-0.023 P = 0.024 - B-0.019 P = 0.058 - B-0.023 P = 0.091 B-0.052 P = 0.039
Cumulative equivalent
prednisolon (gram)
B-0.002 P = 0.024 - B-0.003 P = 0.003 - - -
Variables are tested for their association with change in hip and spine bone density for the follow up periods 0–2 years and 2–10 years in early rheumatoid
arthritis patients using univariate linear regression analysis. Unstandardized Beta values are only shown for variables with a p value ≤ 0.1.
Yrs: Years; N/Y: No/yes; RF: Rheumatoid factor; MHAQ: Modified health assessment questionnaire; ESR: Erythrocyte sedimentation rate; DAS28ESR3: Disease activity
score based on 28 joint count (swollen and tender joints) and ESR; DMARDs: Disease modifying anti-rheumatic drugs.
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study neither ever use of prednisolone nor ever use of
any GC was found to be associated with bone loss. Only
for cumulative equivalent prednisolone doses a signifi-
cant association in adjusted analysis was found to be
associated with bone loss but only at total hip in the 0–2
year period. This must be interpreted with cautiousness
as ever use of biologic DMARDs also was found to be
significantly associated with bone loss at femoral neck in
the first 2 years. This may be explained by that both the
use of biologic treatment and GC in our observational
study behaves as a surrogate marker for disease activity.
It is important to emphasize that bone density data can-
not directly be translated into reduced fracture risk in
patients treated with GC because patients using GC may
have a higher risk of fracture independent of the BMD
level [22].
In our cohort of 92 RA patients with mean age 51 years
at baseline one patient had an ankle and femur fracture
and two other patients suffered clinical costa fracture
during follow up. These numbers of new fractures seem
to be low. In a 5 year follow up study of 102 female RA
patients mean age 61 years with disease duration 17 years
16% of the patients had a new non vertebral fracture
and 19% had a new vertebral fracture on spine X-ray
during follow up [23]. In two studies using data from
health care utilization databases, commercial insurance
plan databases or administrative health care databases
no association between use of biologic therapy and riskof fractures was shown [4,24]. One hypothesis explaining
this negative finding may be that patients treated with
biologic drugs had a higher disease activity than patients
not staring treatment with biologics, thus having a
higher risk of fracture prior to treatment which then was
reduced during treatment. In RA patients registered in
the American CORRONA registry postmenopausal sta-
tus, high mHAQ and prednisolone use was found to be
associated with increased risk of fracture whereas the
use of TNF alone but not in combination with metho-
trexate was reported to be associated with reduced
fracture risk [25].
In our study we found no association between use of
ART and rate of bone loss. ART however has been
shown to reduce bone loss in RA [12]. Surprisingly in
our male RA patients bone density at lumbar spine in-
creased in the 2–10 years period. As we describe in the
Results section this was explained by new bone forma-
tion seen more frequently in men than in women.
Our study does have limitations. One obvious limita-
tion of this study is the missing baseline BMD data from
a rather large proportion of included RA patients. The
same pattern and range of change in BMD using imput-
ation of missing data was however also seen when
patients with available data for all four time points was
analyzed. Thus we believe the missing BMD data at
baseline is not a crucial limitation of our study. Lack of
standardization of treatment also makes it difficult to
explore for associations. However on the other hand our
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tients aggressively treated in ordinary daily clinical practice
in the new millennium. Unfortunately our study was not
design to explore the prevalence and incidence of verte-
bral fractures.
The study design without having age and gender
matched controls from the background population is an-
other obvious limitation. Comparing our data with pre-
vious reports on bone loss in non-RA populations may
indicate that bone loss in RA patients with more sup-
pressed inflammation as seen in the 2–10 years period
approaches the levels reported in the literature [26-29].
In a Finnish population the annual rate of BMD loss was
estimated in cross sectional studies to be −0.2% at lum-
bar spine and −0.3% at femoral neck in men, [27] and in
females above 39 years −0.7% and −1.3%, respectively
[28]. However, in a population followed longitudinally
annual percentage bone loss at total hip was reported to
be 0.0% in men and −0.2% in women [29].
Conclusions
In conclusion our study adds evidence that aggressive
treatment of inflammation especially with biologic
DMARDs in early RA reduces the rate of bone loss signifi-
cantly. These findings are promising and encouraging as
they indicate that modern aggressive treatment can reduce
the burden of osteoporosis in RA patients. Future fracture
studies however are needed to confirm if osteoporotic
fractures in RA are reduced in the new millennium.
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